Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shenzhen Keye Life Technologies Co. Ltd. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is distributed across 1 distinct examiner and 1 distinct art unit. This level of concentration suggests that the company's current patenting efforts are focused on a specific subset of biological or pharmaceutical innovation rather than a broad array of diverse technologies.
The examiner HABTE, KAHSAY is identified as the busiest examiner, holding 1 busiest examiner pending action. Since the total number of pending office actions is 1, this examiner is managing the company's entire active docket. For practitioners, this means that the immediate success of the portfolio relies on the specific feedback and requirements of this 1 examiner within the designated art unit. The alignment of the total pending actions with the busiest examiner's workload highlights a point of focus for the company's current legal strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278234 | Polycyclic Compound for Inhibiting RNA Helicase DHX33, and Application of Compound | HABTE, KAHSAY | 26d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278234 | Polycyclic Compound for Inhibiting RNA Helicase DHX33, and Application of Compound | HABTE, KAHSAY | 1624 | §112 | Final Rejection | 26d | Pending | Aug 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial